Summary.-Fifty-six patients with disseminated malignant melanoma were randomly allocated to two treatment groups. The first group C received combination chemotherapy consisting of DTIC and ICRF 159. The second group (C + I) received the same chemotherapy but were also immunized with 2 x 107 irradiated allogeneic melanoma cells mixed with 50 ,ug of percutaneous BCG. The survival rates in both treatment groups C and (C + I) were not significantly different, and only minor enhancement of the chemotherapy was found in the (C + 1) group. A similar pattern of tissue response was observed in both groups: lymph node, skin and, to some extent liver metastases, respond better than other sites.THE CURRENT treatments for disseminated malignant melanoma are unsatisfactory. Analysis of the patients followed up at the Westminster Hospital in the pretrial period showed that the 2-and 5-year survivals for Stage IIb were 51°/ and 200% respectively. The

No abstract

No abstract